Cohance Lifesciences Limited (BOM:543064)

Cohance Lifesciences Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 8, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Market Capitalization	274,370	172,366	120,256	157,436	126,468	25,590
Market Cap Growth	57.55%	43.33%	-23.61%	24.49%	394.20%	-
Enterprise Value	268,707	165,176	117,048	156,449	127,128	25,590
Last Close Price	1078.65	676.60	472.70	608.03	483.61	98.13
PE Ratio	98.26	57.40	29.24	34.69	34.90	8.07
PS Ratio	26.17	16.40	8.97	11.93	12.53	3.07
PB Ratio	13.53	8.40	6.93	10.31	10.71	3.03
P/TBV Ratio	16.08	8.67	7.19	10.32	10.73	3.04
P/FCF Ratio	-	56.20	70.21	61.79	46.55	8.42
P/OCF Ratio	-	48.08	26.30	47.71	33.06	6.29
EV/Sales Ratio	25.63	15.71	8.73	11.85	12.59	3.07
EV/EBITDA Ratio	73.39	40.65	20.44	27.00	28.85	6.70
EV/EBIT Ratio	86.59	46.59	22.25	28.89	31.02	7.14
EV/FCF Ratio	-	53.86	68.34	61.40	46.79	8.42
Debt / Equity Ratio	0.02	0.03	0.04	0.06	0.12	0.22
Debt / EBITDA Ratio	0.11	0.16	0.12	0.17	0.32	0.49
Debt / FCF Ratio	-	0.21	0.41	0.38	0.53	0.61
Asset Turnover	-	0.50	0.71	0.80	0.76	0.85
Inventory Turnover	-	1.60	1.87	2.24	2.19	1.93
Quick Ratio	-	9.46	4.17	3.85	1.56	0.98
Current Ratio	-	11.82	6.37	5.36	2.57	1.96
Return on Equity (ROE)	-	15.86%	25.21%	33.52%	35.78%	44.18%
Return on Assets (ROA)	-	10.50%	17.33%	20.49%	19.35%	22.90%
Return on Capital (ROIC)	9.50%	11.30%	19.18%	22.96%	21.76%	26.29%
Return on Capital Employed (ROCE)	-	16.50%	29.10%	33.40%	32.70%	36.90%
Earnings Yield	1.02%	1.74%	3.42%	2.88%	2.86%	12.39%
FCF Yield	-	1.78%	1.42%	1.62%	2.15%	11.87%
Dividend Yield	-	-	-	0.33%	0.41%	1.27%
Payout Ratio	-	-	49.52%	11.22%	7.03%	10.04%
Buyback Yield / Dilution	-0.37%	-	-	-	0.00%	0.00%
Total Shareholder Return	-0.37%	-	-	0.33%	0.41%	1.27%

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.